```html

Jaundice, Hemolytic (Hemolytic Anemia)

Overview

Jaundice, hemolytic – often described simply as hemolytic anemia with jaundice – occurs when red blood cells (RBCs) are destroyed faster than the bone marrow can replace them. The rapid breakdown releases bilirubin, a yellow pigment, into the bloodstream, producing the characteristic yellowing of the skin and eyes (jaundice).

Who it affects: The condition can affect anyone, from newborns (physiologic neonatal jaundice) to adults with inherited or acquired disorders. However, certain groups have higher incidence:

• Infants < 2 months old – up to 60 % develop some degree of physiologic jaundice.
• Individuals of African, Mediterranean, or Asian descent – higher prevalence of hereditary enzyme deficiencies such as G6PD deficiency or sickle‑cell disease.
• Patients with autoimmune diseases, certain infections, or exposure to specific medications.

According to the World Health Organization (WHO), hemolytic anemias account for roughly 5‑10 % of all anemia cases worldwide, with an estimated 300 million people carrying hereditary hemolytic traits (e.g., G6PD deficiency). In the United States, sickle‑cell disease affects about 100,000 people, and hereditary spherocytosis occurs in 1 in 2,000–5,000 births. [1][2]

Symptoms

Symptoms reflect two overlapping processes: increased RBC destruction and bilirubin accumulation.

• Jaundice – yellowing of the sclerae (white of the eyes) and skin, often first noticed in the face.
• Fatigue & Weakness – result of reduced oxygen‑carrying capacity.
• Pallor – especially of the conjunctivae and palms.
• Dark urine – presence of hemoglobin or excess bilirubin.
• Light‑colored stools – bilirubin not reaching the intestines.
• Shortness of breath on exertion.
• Headache, dizziness, or fainting – due to low hemoglobin.
• Rapid heart rate (tachycardia) – compensatory response.
• Splenomegaly – an enlarged spleen that may cause left‑upper‑quadrant fullness or pain.
• Gallstones – chronic bilirubin excess can precipitate pigmented gallstones.
• Bone pain – especially in children with marrow expansion.
• Pruritus (itching) – bilirubin can deposit in the skin.
• Neurologic signs (rare) – such as seizures in severe neonatal hyperbilirubinemia.

Symptom severity varies widely; some patients experience only mild jaundice, while others develop life‑threatening anemia.

Causes and Risk Factors

Hemolytic anemia can be **intrinsic** (RBC membrane, enzyme, or hemoglobin defects) or **extrinsic** (immune, mechanical, or infectious). The resulting bilirubin excess yields jaundice.

Intrinsic (Inherited) Causes

• Sickle‑cell disease – abnormal hemoglobin S causing sickling and premature RBC destruction.
• Hereditary spherocytosis – membrane protein defects (ankyrin, spectrin) create spherical, fragile cells.
• Glucose‑6‑phosphate dehydrogenase (G6PD) deficiency – oxidative stress triggers rapid hemolysis.
• Thalassemias – imbalance in globin chain production leads to ineffective erythropoiesis and hemolysis.
• Pyruvate kinase deficiency – impaired glycolysis reduces ATP, weakening RBC membranes.

Extrinsic (Acquired) Causes

• Autoimmune hemolytic anemia (AIHA) – antibodies (IgG or IgM) bind RBCs, leading to destruction.
• Infections – malaria, Clostridium perfringens, or viral hepatitis can lyse RBCs.
• Medications & chemicals – penicillin, cephalosporins, quinine, or certain antimalarials.
• Mechanical trauma – prosthetic heart valves, severe burns, or marching‑band‑style marching.
• Transfusion reactions – ABO incompatibility or delayed hemolytic reactions.

Risk Factors

• Family history of hereditary hemolytic disorders.
• Ethnicity with higher prevalence of specific enzyme deficiencies.
• Recent exposure to known hemolytic drugs or chemicals.
• Underlying autoimmune disease (e.g., lupus).
• Pregnancy (increases risk of AIHA).
• Living in or traveling to malaria‑endemic regions.

Diagnosis

Diagnosing hemolytic anemia with jaundice involves confirming anemia, demonstrating increased RBC destruction, and identifying the underlying cause.

Initial Laboratory Evaluation

• Complete blood count (CBC) – low hemoglobin/hematocrit, often with elevated reticulocyte count (bone‑marrow response).
• Peripheral blood smear – visualizes shape abnormalities (spherocytes, sickle cells, bite cells).
• Serum bilirubin – elevated indirect (unconjugated) bilirubin is typical.
• Lactate dehydrogenase (LDH) – rises with cell breakdown.
• Haptoglobin – low or undetectable because it binds free hemoglobin.
• Direct antiglobulin test (Coombs) – positive in immune‑mediated hemolysis.

Specialized Tests

• Enzyme assays – G6PD activity, pyruvate kinase levels.
• Hemoglobin electrophoresis – identifies sickle‑cell disease, thalassemia.
• Genetic testing – increasingly used for definitive diagnosis of hereditary forms.
• Ultrasound of the abdomen – assesses splenomegaly or gallstones.
• Blood cultures – if infection is suspected.

Diagnostic Criteria

Most clinicians rely on the combination of (1) anemia with reticulocytosis, (2) laboratory evidence of hemolysis (high LDH, low haptoglobin, indirect hyperbilirubinemia), and (3) a plausible etiology confirmed by targeted testing.

Treatment Options

Treatment is individualized according to the cause, severity, and patient’s overall health.

General Measures

• Folic acid supplementation – 1 mg daily to support erythropoiesis.
• Hydration – reduces risk of pigmented gallstones and supports renal clearance of hemoglobin.
• Transfusion therapy – reserved for symptomatic severe anemia (Hb < 7 g/dL) or hemodynamic instability.

Cause‑Specific Therapies

Inherited Enzyme Deficiencies

• Avoidance of triggers – e.g., sulfa drugs, fava beans for G6PD deficiency.
• Acute hemolysis – supportive care; severe cases may need exchange transfusion.

Sickle‑Cell Disease

• Hydroxyurea – increases fetal hemoglobin, reducing sickling episodes.
• Chronic transfusion programs – prevent stroke in high‑risk children.
• Bone‑marrow or gene therapy – curative options under clinical investigation.

Autoimmune Hemolytic Anemia

• Corticosteroids (prednisone 1 mg/kg/day) – first‑line immunosuppression.
• Rituximab or IVIG – for steroid‑refractory cases.
• Spleen removal (splenectomy) – considered when hemolysis persists despite medication.

Mechanical/Traumatic Causes

• Repair or replace faulty prosthetic valves.
• Discontinue offending drugs.

Adjunctive Treatments for Jaundice

• Phototherapy – mainstay for severe neonatal indirect hyperbilirubinemia.
• Exchange transfusion – life‑saving in neonates with bilirubin > 20 mg/dL or signs of kernicterus.
• Ursodeoxycholic acid – may aid gallstone prevention in chronic cases.

Living with Jaundice, Hemolytic (Hemolytic Anemia)

Long‑term management focuses on monitoring, lifestyle adaptation, and prompt attention to triggers.

Monitoring

• Quarterly CBC and reticulocyte count if stable; more frequent during crises.
• Annual liver function tests and bilirubin levels.
• Vision of the spleen via ultrasound every 2–3 years (or sooner if symptoms change).

Daily Lifestyle Tips

• Nutrition: High‑folate diet (leafy greens, beans), adequate protein, and limited iron supplements unless iron‑deficiency coexists.
• Stay hydrated: Aim for ≥ 2 L/day unless fluid‑restricted.
• Sun protection: Jaundice may increase photosensitivity in some drug‑induced cases.
• Medication review: Keep an up‑to‑date list; inform every prescriber of hemolysis risk.
• Vaccinations: Patients without a spleen need pneumococcal, meningococcal, and Haemophilus influenzae type b vaccines.
• Exercise: Moderate activity improves cardiovascular health; avoid extreme altitude where oxygen is low.

Psychosocial Support

Chronic anemia can affect mood and energy. Consider counseling, support groups (e.g., Sickle Cell Disease Association), and patient education programs.

Prevention

• Genetic counseling for families with known hereditary hemolytic disorders.
• Screen newborns for G6PD deficiency and other common traits (standard in many countries).
• Avoidance of known hemolytic triggers – fava beans, certain antibiotics, and oxidative chemicals.
• Prompt treatment of infections, especially malaria prophylaxis when traveling.
• Regular prenatal care – maternal autoimmune diseases can be identified and controlled early.

Complications

If the underlying hemolysis or bilirubin excess is not controlled, several serious complications may develop:

• Kernicterus – bilirubin‑induced brain injury, mainly in neonates with very high levels.
• Gallstones (pigment stones) – can cause biliary colic, cholecystitis, or pancreatitis.
• Iron overload – especially after repeated transfusions; may damage liver, heart, and endocrine organs.
• Splenic sequestration – sudden pooling of blood in an enlarged spleen leading to hypovolemic shock.
• Bone marrow expansion – causing facial bone deformities in severe chronic hemolysis.
• Thromboembolic events – especially in sickle‑cell disease.
• Infections – asplenic or functional hyposplenic patients have higher risk for encapsulated bacteria.

When to Seek Emergency Care

---

Sources:
[1] Mayo Clinic. “Hemolytic anemia.” https://www.mayoclinic.org.
[2] Centers for Disease Control and Prevention. “Sickle Cell Disease.” https://www.cdc.gov.
[3] National Heart, Lung, and Blood Institute. “G6PD Deficiency.” https://www.nhlbi.nih.gov.
[4] World Health Organization. “Guidelines for the Management of Neonatal Jaundice.” 2022.
[5] Cleveland Clinic. “Autoimmune Hemolytic Anemia.” https://my.clevelandclinic.org.

```